(Press-News.org) Barcelona, 19 September 2012. The Vall d'Hebron Breast Cancer Unit, the Vall d'Hebron Institute of Oncology (VHIO) and SOLTI, an academic breast cancer research group , are heading up a multi-centre international study involving four Spanish and three North American research centres*. The aim of the study is to investigate whether BKM120, a drug that inhibits the PI3K pathway (phosphatidylinositol-3-Kinase) can be an effective treatment against triple-negative breast cancer.
At present it is known that breast cancer can be classified into different subtypes with varying prognoses and responses to treatment. This classification is essentially based on the presence of hormone receptors (oestrogen and progesterone) and the HER2 receptor. In clinical practice this has led to the development of increasingly selective and optimal treatments for patients. Advances in breast cancer treatment using new drugs on accurately-selected populations, along with the implementation of public screening programs, have contributed in recent years to reducing mortality from this disease.
Triple-negative breast cancer: the most aggressive form
Triple-negative breast cancer is defined by the absence of hormone receptors and HER2. This type of breast cancer is an aggressive variety of the disease that generally appears in younger women. Few treatment options beyond chemotherapy and anti-angiogenic agents are currently available. The present study aims to test whether BKM120 is effective for these patients and also, by means of biomarkers in the blood or in the tumour, identify which tumours respond to this new treatment.
The design initiative for this study falls within the grant awarded by the organization Stand Up to Cancer (SU2C), a non-profit entity whose objectives include supporting translational cancer research to ensure that the benefits of the most innovative treatments resulting from basic research can rapidly reach patients through study designs that allow fast-track application of the results.
"Dream Teams" against cancer
SU2C promotes the formation of multidisciplinary teams, known as "Dream Teams", which bring together the talent and knowledge of top scientists and cancer specialists from all over the world, bringing added value to research and allowing the rapid transfer of findings from basic research to clinical application.
Each Dream Team is made up of leading experts in certain tumour types and receives funding to develop their respective project over a three-year period in a highly collaborative and independent environment. The removal of bureaucratic barriers prevents part of the funding being lost through intermediaries, allowing experts to concentrate exhaustively on their research. This structure has been designed to obtain the optimum results with the highest assurance in the shortest possible time.
The team of Dr José Baselga from the VHIO is one of the Dream Teams selected by SU2C to take part in this ambitious project and head up the study on BKM 120 for the treatment of triple-negative breast cancer. This top-level collaboration stems from the experience and knowledge of the groups of excellence in the Breast Cancer Unit and the Research Unit for the Molecular Therapy of Cancer - "la Caixa" at the VHIO, headed respectively by Dr Javier Cortés and Dr Jordi Rodón, as well as the expertise of SOLTI in coordinating multi-centre academic studies.
The Research Unit for the Molecular Therapy of Cancer (UITM) "la Caixa" and the Breast Cancer Unit already boast four years' experience in researching a broad spectrum of PI3K pathway inhibitors. They recently presented a study at the Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, June 1 - 5, 2012, on the actions of these drugs in patients suffering from breast cancer, in monotherapy or in combination with other treatments. "This study, with data from the largest patient sample ever used, presents some encouraging findings with regard to the control time of the disease in metastatic patients," explains Dr Cristina Saura, the study coordinator in Spain as a member of SOLTI.
Innovations in breast cancer treatment
The PI3K pathway regulates key cellular functions such as cell growth, proliferation and survival. The appearance of mutations in this pathway is common and seems to contribute to the development of certain types of cancer in women, such as cancers of the breast, ovaries, uterus and endometrium. These mutations have also been implicated in the resistance mechanisms to certain conventional treatments (chemotherapy, hormone treatment or Trastuzumab).
The study that is already underway and open at the Vall d'Hebron University Hospital is a Phase II trial with a specific PI3K pathway inhibitor – the molecule BKM120 – and "the trial aims to determine the clinical activity of the molecule in patients with triple-negative metastatic breast cancer at an advanced stage of the disease still progressing following treatment with chemotherapy," comments Dr Javier Cortés, the Head of the Breast Cancer Unit, and continues, "we are thus talking about advanced disease treatment, when the tumour has progressed to standard treatment options".
One of the novel aspects of this project is that it has been specifically designed to determine, by an analysis of the genetic profiles of patients, whether there is an identifiable subgroup of patients that particularly responds to this treatment. "The analysis of the genetic profiles of patients who respond and those who don't will help us to understand the reasons for this response, thanks to the technology and specialist knowledge that only this Dream Team possesses, which gives it a unique value," explains Dr Rodón, Head of the UITM and principal researcher of this international study.
The study with BKM120 is an example of how the highest level of technology combined with excellence in biomedical research can translate into major benefits for patients. Future lines of research will be directed at the exploration and validation of new predictive biomarkers, bringing us one step closer to realising the promise of personalized medicine. It is becoming increasingly necessary to search for biomarkers of response to these molecules in order to determine, prior to treatment, which patients are going to benefit from this treatment and why.
###
*The Spanish centers involved in the BKM120 trial are: the University Hospital of Vall d'Hebron in Barcelona, the Valencian Institute of Oncology at the University Hospital of Valencia, and the 12 de Octubre Hospital in Madrid. Three North American centers are also expected to participate: the Dana-Farber Cancer Institute, the Beth Israel Deaconess Medical Centre, and the Dana-Farber Clinic at Faulkner Hospital, all in Boston, MA.
Vall d’Hebron, VHIO and SOLTI head up an international 'dream team' against breast cancer
2012-09-19
ELSE PRESS RELEASES FROM THIS DATE:
War causes mental illness in soldiers
2012-09-19
One in every two cases of post-traumatic stress disorder (PTSD) in soldiers remains undiagnosed. This is the conclusion reached by a working group led by Hans-Ulrich Wittchen et al. They report their study in the current issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2012; 109(35): 559), which is a special issue focusing on the prevalence of psychological stress in German army soldiers. In a second original article, results reported by Jens T Kowalski and colleagues show that more female soldiers contact the psychosocial support services provided by Germany's ...
How close were we to armageddon? 50 years on, why should we still study the Cuban Missile Crisis?
2012-09-19
Why, fifty years on, is the Cuban Missile Crisis still a subject of considerable fascination for academics and professionals alike? Should we still be studying it, and if so, how? These are just some of the questions addressed in a special issue in the journal International Relations, published by SAGE.
As one of the most intensely studied events of the twentieth century, the Cuban Missile Crisis could suffer from "over examination", yet as Guest Editor Len Scott, Professor of International Politics and Dean of Social Science at Aberystwyth University, remarks: "While ...
Self-forming biological scaffolding
2012-09-19
A new model system of the cellular skeletons of living cells is akin to a mini-laboratory designed to explore how the cells' functional structures assemble. A paper about to be published in EPJ E by physicist Volker Schaller and his colleagues from the Technical University Munich, Germany, presents one hypothesis concerning self-organisation. It hinges on the findings that a homogeneous protein network, once subjected to stresses generated by molecular motors, compacts into highly condensed fibres.
The contractile machinery inside cells is arguably the most prominent ...
Angling for gold
2012-09-19
A study on how gold atoms bond to other atoms using a model that takes into account bonds direction has been carried out by physicist Marie Backman from the University of Helsinki, Finland, and colleagues. These findings, which are about to be published in EPJ B, are a first step toward better understanding how gold binds to other materials through strong, so-called covalent, bonds.
What scientists need is an empirical model, based on a so-called potential, that describes the gold-gold bond in a reliable way. Most previous models only accounted for interactions in the ...
Barack Obama good for Israel; Barack Hussein Obama less so
2012-09-19
President Obama's middle name, Hussein, makes Israelis – both Jewish and Arab – perceive him as less pro-Israeli, reveals a new study conducted by the University of Haifa and the University of Texas. The study has just been published in the journal Political Behavior. "Even though the Israeli public has extensive information about the American President and his positions, their opinions can still be swayed by cultural cues, such as a name that in this case is perceived as Arabic," says Dr. Israel Waismel-Manor of the University of Haifa who co-authored the study.
Similar ...
NEIKER and INRA discover that BDA symptoms in grapevine leaves are a sign of esca
2012-09-19
This press release is available in Spanish.Scientists at the Basque Institute of Agricultural Research and Development, NEIKER-Tecnalia, and the National Institute of Agricultural Research in Bordeaux (INRA) have come to the conclusion that alleged symptoms of 'black dead arm' (BDA) on grapevine leaves are, in fact, those of esca disease in its initial phase. Esca and BDA are diseases that affect the trunk of vines and cause serious losses to the wine-making and grape-growing sectors every year.
The symptoms produced by esca and BDA in vine leaves are reminiscent of ...
Preemies' brains reap long-term benefits from Kangaroo Mother Care
2012-09-19
This press release is available in French.Quebec City, September 19, 2012—Kangaroo Mother Care -- a technique in which a breastfed premature infant remains in skin-to-skin contact with the parent's chest rather than being placed in an incubator -- has lasting positive impact on brain development, revealed Université Laval researchers in the October issue of Acta Paediatrica. Very premature infants who benefited from this technique had better brain functioning in adolescence -- comparable to that of adolescents born at term -- than did premature infants placed in incubators.
Earlier ...
Stop diabetes with insulin tablets
2012-09-19
Type 1 diabetes is the autoimmune form of diabetes, in which the patients' insulin-producing beta cells are destroyed by their own immune system.
"We know that if a person has two autoantibodies and one of them is against insulin, there is a 50 per cent risk that they will develop type 1 diabetes within five years. It doesn't matter how old you are", says Åke Lernmark, Professor of Experimental Diabetes Research at Lund University in Sweden.
"There are indications that oral insulin may prevent or delay the clinical onset of type 1 diabetes among individuals with autoantibodies ...
Fighting melanoma's attraction to the brain
2012-09-19
The process of metastasis, by which cancer cells travel from a tumor site and proliferate at other sites in the body, is a serious threat to cancer patients. According to the National Cancer Institute, most recurrences of cancer are metastases rather than "new" cancers.
Virtually all types of cancer can spread to other parts of the body, including the brain. Once metastatic melanoma cells are entrenched in the brain, patients typically have only a few months to live.
Now Prof. Isaac Witz and his team at Tel Aviv University's Department of Cell Research and Immunology ...
Carbon dioxide from water pollution, as well as air pollution, may adversely impact oceans
2012-09-19
Carbon dioxide (CO2) released into the oceans as a result of water pollution by nutrients — a major source of this greenhouse gas that gets little public attention — is enhancing the unwanted changes in ocean acidity due to atmospheric increases in CO2. The changes may already be impacting commercial fish and shellfish populations, according to new data and model predictions published today in ACS's journal, Environmental Science & Technology.
William G. Sunda and Wei-Jun Cai point out that atmospheric levels of CO2, the main greenhouse gas, have increased by about 40 ...